Markus Rey

1.2k total citations
29 papers, 934 citations indexed

About

Markus Rey is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Markus Rey has authored 29 papers receiving a total of 934 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Cardiology and Cardiovascular Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Markus Rey's work include Sphingolipid Metabolism and Signaling (8 papers), Nitric Oxide and Endothelin Effects (6 papers) and Pulmonary Hypertension Research and Treatments (6 papers). Markus Rey is often cited by papers focused on Sphingolipid Metabolism and Signaling (8 papers), Nitric Oxide and Endothelin Effects (6 papers) and Pulmonary Hypertension Research and Treatments (6 papers). Markus Rey collaborates with scholars based in Switzerland, China and France. Markus Rey's co-authors include Patrick Hess, Martine Clozel, Marc Iglarz, Changbin Qiu, Christoph A. Binkert, Oliver Nayler, Magdalena Birker, Thomas Weller, Beat Steiner and Martin H. Bolli and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Markus Rey

28 papers receiving 916 citations

Peers

Countries citing papers authored by Markus Rey

Since Specialization

Citations

This map shows the geographic impact of Markus Rey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Rey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Rey more than expected).

Fields of papers citing papers by Markus Rey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Rey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Rey. The network helps show where Markus Rey may publish in the future.

Co-authorship network of co-authors of Markus Rey

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Rey. A scholar is included among the top collaborators of Markus Rey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Rey. Markus Rey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia 2025 ·Bioorganic & Medicinal Chemistry ·Jean‐Philippe Surivet, (unknown), Melanie Keßler, Christopher Kohl, Catherine Vaillant, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jens‐Uwe Peters, (unknown), Markus Rey, (unknown), Michel A. Steiner	0
2	Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies 2023 ·Journal of Medicinal Chemistry ·Emmanuel A. Meyer, (unknown), Eric A. Ertel, (unknown), Daniel S. Strasser, Markus Rey, Mark Murphy, Marianne M. Martinic, (unknown), (unknown), Marcel P. Keller, (unknown)	6
3	The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo 2021 ·Journal of Clinical Medicine ·Lydie Crescence, (unknown), (unknown), Markus Rey, Sébastiên Roux, Laurence Panicot‐Dubois, Christophe Dubois, Markus A. Riederer	7
4	Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension 2019 ·Journal of Pharmacology and Experimental Therapeutics ·F. Trensz, (unknown), (unknown), (unknown), (unknown), Markus Rey, Daniel S. Strasser, Stéphane Delahaye, Patrick Hess, Enrico Vezzali, (unknown), Joël Ménard, Martine Clozel, Marc Iglarz	42
5	S1P1 Modulator-Induced Gi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo 2017 ·Molecular Pharmacology ·Magdalena Birker, Martin H. Bolli, Markus Rey, Ruben de Kanter, Christopher Kohl, Cyrille Lescop, (unknown), (unknown), Beat Steiner, Oliver Nayler	4
6	Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies 2017 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Romain Siegrist, (unknown), (unknown), Davide Pozzi, Olivier Corminboeuf, Catherine Roch, Melanie Keßler, Eric A. Ertel, Isabelle Reymond, Thomas Pfeifer, Ruben de Kanter, (unknown), (unknown), (unknown), Richard Moon, Markus Rey, (unknown), Elvire Fournier	44
7	Cenerimod, a novel selective S1P₁ receptor modulator with unique signaling properties 2017 ·Pharmacology Research & Perspectives ·Luca Piali, Magdalena Birker, Cyrille Lescop, Sylvie Froidevaux, Nicole Schmitz, Keith Morrison, Christopher Kohl, Markus Rey, R. O. Studer, Enrico Vezzali, Patrick Hess, Martine Clozel, Beat Steiner, Martin H. Bolli, Oliver Nayler	26
8	Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines 2016 ·European Journal of Medicinal Chemistry ·Martin H. Bolli, Cyrille Lescop, Magdalena Birker, Ruben de Kanter, Patrick Hess, Christopher Kohl, Oliver Nayler, Markus Rey, Patrick Sieber, (unknown), Thomas Weller, Beat Steiner	12
9	Novel S1P 1 receptor agonists – Part 4: Alkylaminomethyl substituted aryl head groups 2016 ·European Journal of Medicinal Chemistry ·Cyrille Lescop, (unknown), (unknown), Magdalena Birker, Ruben de Kanter, Christopher Kohl, Patrick Hess, Oliver Nayler, Markus Rey, Patrick Sieber, Beat Steiner, Thomas Weller, Martin H. Bolli	11
10	Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers 2016 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Dennis M. Downing, John Gatfield, Catherine Roch, Melanie Keßler, Johannes Mosbacher, Thomas Pfeifer, Corinna Grisostomi, Markus Rey, Eric A. Ertel, Richard Moon	19
11	Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers 2015 ·Bioorganic & Medicinal Chemistry Letters ·Dorte Renneberg, (unknown), Markus Rey, Patrick Hess, Stéphane Delahaye, John Gatfield, Marc Iglarz, Kurt Hilpert	4
12	A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis 2014 ·American Journal of Respiratory Cell and Molecular Biology ·Yasmina Bauer, John Tedrow, Simon de Bernard, Magdalena Birker, Kevin F. Gibson, Brenda Juan Guardela, Patrick Hess, Axel Klenk, Kathleen O. Lindell, (unknown), Bérengère Renault, Markus Rey, Edgar Weber, Oliver Nayler, Naftali Kaminski	122
13	Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension 2014 ·Life Sciences ·Marc Iglarz, (unknown), (unknown), (unknown), Markus Rey, Patrick Hess, Martine Clozel	37
14	Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P1 Receptor Modulator 2013 ·PLoS ONE ·Markus Rey, Patrick Hess, Martine Clozel, Stéphane Delahaye, John Gatfield, Oliver Nayler, Beat Steiner	14
15	Novel S1P₁ Receptor Agonists – Part 1: From Pyrazoles to Thiophenes 2013 ·Journal of Medicinal Chemistry ·Martin H. Bolli, (unknown), (unknown), Stefan Abele, Magdalena Birker, Roberto Bravo, Daniel Bur, Patrick Hess, Christopher Kohl, David F. Lehmann, Oliver Nayler, Markus Rey, Solange Meyer, Michael W. Scherz, G. Schmidt, Beat Steiner, Alexander Treiber, (unknown), Thomas Weller	18
16	Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists 2012 ·Marc Iglarz, Markus Rey, Patrick Hess, Katalin Kauser, Martine Clozel	2
17	Optimization Of Tissue Targeting Properties Of Macitentan, A New Dual Endothelin Receptor Antagonist, Improves Its Efficacy In A Rat Model Of Pulmonary Fibrosis Associated With Pulmonary Arterial Hypertension 2011 ·Marc Iglarz, (unknown), Markus Rey, (unknown), Patrick Hess, Martine Clozel	14
18	The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Martine Clozel, Patrick Hess, Changbin Qiu, (unknown), Markus Rey	71
19	Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. 2006 ·PubMed ·Martine Clozel, Patrick Hess, Markus Rey, Marc Iglarz, Christoph A. Binkert, Changbin Qiu	78
20	Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Martine Clozel, Christoph A. Binkert, Magdalena Birker, (unknown), Shuangshuang Ding, Walter Fischli, Patrick Hess, (unknown), Keith Morrison, (unknown), (unknown), Oliver Nayler, Changbin Qiu, Markus Rey, Michael W. Scherz, (unknown), Thomas Weller, (unknown), (unknown)	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact